POLAR study
Research type
Research Study
Full title
Molecular predictors of early versus late recurrence in ER positive, HER2 negative breast cancer.
IRAS ID
138284
Contact name
Mitch Dowsett
Contact email
Sponsor organisation
Clinical R&D Manager
Research summary
In ER positive breast cancer as many recurrences occur beyond five years as in the initial five years of follow up. Adjuvant endocrine therapy has made a substantial impact in reducing recurrence and improving survival for patients with ER positive disease. Recent evidence suggests that longer adjuvant endocrine therapy may be better, albeit with some potential additional toxicity (Goss et al 2005; Davies et al 2013). To date, it has not been established which patients derive benefit from extended therapy and which may be spared continuing endocrine therapy beyond 5 years. Thus a test to predict those at risk of late recurrence would be of immediate and substantial value for patient management.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
14/WM/0140
Date of REC Opinion
15 Apr 2014
REC opinion
Favourable Opinion